Novocure's electromagnetic fields stop lung cancer

Shares of Novocure (in our portfolios) skyrocketed after the company announced positive results for its much-awaited LUNAR Phase 3 study - a study for one of the deadliest known cancer, Non-Small Cell Lung Cancer (NSCLC).

Bottom line

Novocure just released topline readouts for LUNAR, a late-stage study evaluating Tumor Treating Field (TTF) therapy in treating non-small cell lung cancer. The full data will be presented later, but the early success demonstrates, once again, the potential of TTF to extend patients' lives with very low side effects. The INNOVATE-3 clinical readout (ovarian cancer) will come in mid-2023, followed by results from METIS (brain metastases) and PANOVA-3 (pancreatic cancer) in 2024. These indications can potentially expand the company's addressable market ~20 times. 

This article is available to logged users.
Sign in or request a login.



This report has been produced by the organizational unit responsible for investment research (Research unit) of atonra Partners and sent to you by the company sales representatives.

As an internationally active company, atonra Partners SA may be subject to a number of provisions in drawing up and distributing its investment research documents. These regulations include the Directives on the Independence of Financial Research issued by the Swiss Bankers Association. Although atonra Partners SA believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report.

The information contained in these publications is exclusively intended for a client base consisting of professionals or qualified investors. It is sent to you by way of information and cannot be divulged to a third party without the prior consent of atonra Partners. While all reasonable effort has been made to ensure that the information contained is not untrue or misleading at the time of publication, no representation is made as to its accuracy or completeness and it should not be relied upon as such.

Past performance is not indicative or a guarantee of future results. Investment losses may occur, and investors could lose some or all of their investment. Any indices cited herein are provided only as examples of general market performance and no index is directly comparable to the past or future performance of the Certificate.

It should not be assumed that the Certificate will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between the Certificate’s returns and any index returns.

Any material provided to you is intended only for discussion purposes and is not intended as an offer or solicitation with respect to the purchase or sale of any security and should not be relied upon by you in evaluating the merits of investing inany securities.